Navalkissoor, S;
Flux, G;
Bomanji, J;
(2017)
Molecular radiotheranostics for neuroendocrine tumours.
Clinical Medicine
, 17
(5)
pp. 462-468.
10.7861/clinmedicine.17-5-462.
Preview |
Text
Bomanji_462.full.pdf - Published Version Download (381kB) | Preview |
Abstract
This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.
| Type: | Article |
|---|---|
| Title: | Molecular radiotheranostics for neuroendocrine tumours |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.7861/clinmedicine.17-5-462 |
| Publisher version: | https://doi.org/10.7861/clinmedicine.17-5-462 |
| Language: | English |
| Additional information: | This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | 177Lu,90Y, MIBG, PRRT, somatostatin receptor scintigraphy, Humans, Neuroendocrine Tumors, Radionuclide Imaging |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10029096 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
